BAUSCH + LOMB PHARMACEUTICAL RETINA PORTFOLIO

Explore these products to help you manage patients in your practice

The Bausch + Lomb Pharmaceutical Retina Portfolio is available to help you meet your patients' therapeutic needs. We know you have many choices when it comes to treating your patients.

Personalized patient assistance programs are available from Bausch + Lomb for these treatment options.

FOCUSED ON YOU AND YOUR PATIENTS

For information and Patients Assistances Services, call the FOCUS ON ACCESS™ Hotline
(866)-272-8838 | Monday - Friday, 9AM to 5PM EST

Download FOA Enrollment Form

INDICATION AND IMPORTANT SAFETY INFORMATION

XIPERE®

XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

XIPERE® is contraindicated in patients with active or suspected ocular or periocular infections including most viral dieses of the cornea and conjunctiva, including active epithelial simplex (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.

Click here for additional Important Safety Information For XIPERE®

Please click here for full XIPERE® Prescribing Information.

RETISERT®

RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.

Surgical placement of RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg is contraindicated in active viral, bacterial, mycobacterial or fungal infections of the eye.

Click here for additional Important Safety Information for RETISERT®

Please click here for full RETISERT® Prescribing Information.

VISUDYNE®

VISUDYNE® (verteporfin for injection) therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV.

VISUDYNE® (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any component of this preparation.

Click here for additional Important Safety Information for VISUDYNE®

Please click here for full VISUDYNE® Prescribing Information.